Search Results for "activate"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for activate. Results 391 to 400 of 1332 total matches.

Problems With Dietary Supplements

   
The Medical Letter on Drugs and Therapeutics • Sep 30, 2002  (Issue 1140)
and mid-1999 found that the concentrations of listed ingredients thought to be active varied from lot ...
Millions of people now take herbal products and other "dietary supplements." The Physicians' Desk Reference has published a PDR for Herbal Medicines listing their ingredients and indications, and the Drug Topics Red Book lists their prices.
Med Lett Drugs Ther. 2002 Sep 30;44(1140):84-6 |  Show IntroductionHide Introduction

Adefovir (Hepsera) for Chronic Hepatitis B Infection

   
The Medical Letter on Drugs and Therapeutics • Dec 09, 2002  (Issue 1145)
of chronic active infection with hepatitis B virus (HBV). In 1999, because of concerns about renal toxicity ...
Adefovir dipivoxil (Hepsera - Gilead), a nucleotide analog, has been approved by the FDA for oral treatment of chronic active infection with hepatitis B virus (HBV). In 1999, because of concerns about renal toxicity, the FDA rejected a higher-dosage formulation of adefovir for treatment of HIV infection.
Med Lett Drugs Ther. 2002 Dec 9;44(1145):105-6 |  Show IntroductionHide Introduction

Augmentin XR

   
The Medical Letter on Drugs and Therapeutics • Jan 20, 2003  (Issue 1148)
, a cephalosporin such as cefuroxime axetil, or a quinolone with good antipneumococcal activity such as gatifloxacin ...
Augmentin XR (GlaxoSmithKline), an oral extended-release combination of amoxicillin and the beta-lactamase inhibitor clavulanic acid, is now being promoted for treatment of acute bacterial sinusitis and community-acquired pneumonia. Augmentin XR contains a higher dose of amoxicillin than Augmentin.
Med Lett Drugs Ther. 2003 Jan 20;45(1148):5-6 |  Show IntroductionHide Introduction

Resveratrol

   
The Medical Letter on Drugs and Therapeutics • Sep 21, 2009  (Issue 1321)
. MECHANISM OF ACTION — Resveratrol increases the activity of some sirtuin enzymes thought to be involved ...
Resveratrol is a phytochemical found in the skin of red grapes and in many other plants, including berries, plums and peanuts. As a constituent of red wine, it has been associated with cardioprotective effects. Dietary supplements containing resveratrol are now being widely promoted as antioxidants that can prevent agerelated diseases.
Med Lett Drugs Ther. 2009 Sep 21;51(1321):74-5 |  Show IntroductionHide Introduction

Prasterone (Intrarosa) for Dyspareunia

   
The Medical Letter on Drugs and Therapeutics • Sep 11, 2017  (Issue 1529)
, and brain and converted intracellularly into active metabolites of estrogens and androgens. DHEA ...
The FDA has approved the steroid prasterone (Intrarosa – Endoceutics) for intravaginal treatment of postmenopausal women with moderate-to-severe dyspareunia due to vulvovaginal atrophy (VVA). Also called dehydroepiandrosterone (DHEA), prasterone is produced in the adrenal glands, gonads, and brain and converted intracellularly into active metabolites of estrogens and androgens. DHEA has been available over the counter for years as an oral dietary supplement claimed to benefit sexual, cardiovascular, and neuropsychiatric dysfunction.
Med Lett Drugs Ther. 2017 Sep 11;59(1529):149-50 |  Show IntroductionHide Introduction

Vibegron (Gemtesa) for Overactive Bladder

   
The Medical Letter on Drugs and Therapeutics • May 03, 2021  (Issue 1623)
whole or crushed and mixed with applesauce. MECHANISM OF ACTION — Like mirabegron, vibegron activates ...
The FDA has approved the selective beta-3 adrenergic agonist vibegron (Gemtesa – Urovant Sciences) for treatment of overactive bladder in adults with symptoms of urge urinary incontinence, urgency, and urinary frequency. It is the second beta-3 agonist to be approved in the US; mirabegron (Myrbetriq) was the first.
Med Lett Drugs Ther. 2021 May 3;63(1623):67-9 |  Show IntroductionHide Introduction

Berotralstat (Orladeyo) for Prevention of Hereditary Angioedema (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 26, 2021  (Issue 1629)
activation and production of bradykinin by covalently binding to and inactivating plasma kallikrein ...
Berotralstat (Orladeyo – Biocryst), an oral plasma kallikrein inhibitor, has been approved by the FDA for prevention of hereditary angioedema (HAE) attacks in adults and children ≥12 years old. The subcutaneously-injected plasma kallikrein inhibitor lanadelumab-flyo (Takhzyro) and the human plasma-derived C1 esterase inhibitors (C1INHs) Cinryze, which is given IV, and Haegarda, which is given SC, have been available for prophylaxis of HAE for years.
Med Lett Drugs Ther. 2021 Jul 26;63(1629):e7-8 |  Show IntroductionHide Introduction

DaxibotulinumtoxinA (Daxxify) for Frown Lines (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024  (Issue 1707)
with corrugator and/or procerus muscle activity. Daxxify is the fifth botulinumtoxin type A product to be approved ...
The FDA has approved daxibotulinumtoxinA-lanm (Daxxify – Revance), an acetylcholine release inhibitor and neuromuscular blocking agent, for temporary improvement in the appearance of moderate to severe glabellar (frown) lines associated with corrugator and/or procerus muscle activity. Daxxify is the fifth botulinumtoxin type A product to be approved in the US for this indication (see Table 1). It is also approved for treatment of cervical dystonia in adults
Med Lett Drugs Ther. 2024 Jul 22;66(1707):e121-2   doi:10.58347/tml.2024.1707g |  Show IntroductionHide Introduction

Drug Interactions

   
The Medical Letter on Drugs and Therapeutics • Jun 08, 2003  (Issue 1158)
, but usually not to a clinically important degree. Drugs that inhibit the activity of CYP isozymes without ...
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Med Lett Drugs Ther. 2003 Jun 8;45(1158):46-8 |  Show IntroductionHide Introduction

Atazanavir (Reyataz) and Emtricitabine (Emtriva) for HIV Infection

   
The Medical Letter on Drugs and Therapeutics • Nov 10, 2003  (Issue 1169)
. Emtricitabine is a fluorinated derivative of lamivudine. Like lamivudine, it is also active against hepatitis B ...
Atazanavir (Reyataz - Bristol-Myers Squibb), a new protease inhibitor (PI), and emtricitabine (Emtriva - Gilead), a nucleoside analogue reverse transcriptase inhibitor (NRTI) chemically similar to lamivudine, have been approved by the FDA for treatment of HIV-1 infection. Both are taken once daily, unlike most anti-HIV drugs.
Med Lett Drugs Ther. 2003 Nov 10;45(1169):90-2 |  Show IntroductionHide Introduction